Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Predictors of Success for Pulmonary Vein Isolation With Pulsed-field Ablation Using a Variable-loop Catheter With 3D Mapping Integration: Complete 12-month Outcomes From inspIRE

T. De Potter, M. Grimaldi, M. Duytschaever, A. Anic, J. Vijgen, P. Neuzil, H. Van Herendael, A. Verma, A. Skanes, D. Scherr, H. Pürerfellner, G. Rackauskas, P. Jais, VY. Reddy, inspIRE Trial Investigators

. 2024 ; 17 (5) : e012667. [pub] 20240424

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, klinické zkoušky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014069

BACKGROUND: We previously presented the safety and early efficacy of the inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed-field Ablation [PFA] System With Irreversible Electroporation [IRE]). With the study's conclusion, we report the outcomes of the full pivotal study cohort, with an additional analysis of predictors of success. METHODS: InspIRE was a prospective, multicenter, single-arm clinical trial of drug-refractory paroxysmal atrial fibrillation. Pulmonary vein isolation was performed with a variable-loop circular catheter integrated with a 3-dimensional mapping system. Follow-up with 24-hour Holter was at 3, 6, and 12 months, as well as remote rhythm monitoring: weekly from 3 to 5 months, monthly from 6 to 12 months, and for symptoms. The primary effectiveness end point (PEE) was acute pulmonary vein isolation plus freedom from any atrial arrhythmia at 12 months. Additional subanalyses report predictors of PEE success. RESULTS: The patient cohort included 186 patients: aged 59±10 years, female 30%, and CHA2DS2-VASc 1.3±1.2. The previously reported primary adverse event rate was 0%. One serious procedure-related adverse event, urinary retention, was reported. The PEE was achieved in 75.6% (95% CI, 69.5%-81.8%). The clinical success of freedom from symptomatic recurrence was 81.7% (95% CI, 76.1%-87.2%). Simulating a monitoring method used in standard real-world practice (without protocol-driven remote rhythm monitoring), this translates to a freedom from all and symptomatic recurrence of 85.8% (95% CI, 80.8%-90.9%) or 94.0% (95% CI, 90.6%-97.5%), respectively. Multivariate analyses revealed that left ventricular ejection fraction ≥60% (adjusted odds ratio, 0.30) and patients receiving ≥48 PFA applications (adjusted odds ratio, 0.28) were independent predictors of PEE success. Moreover, PEE success was 79.2% in patients who received ≥12 PFA applications per vein compared with 57.1% in patients receiving fewer PFA applications. CONCLUSIONS: The inspIRE study confirms the safety and effectiveness of pulmonary vein isolation using the novel 3-dimensional mapping integrated circular loop catheter. An optimal number of PFA applications (≥48 total or ≥12 per vein) resulted in an improved 1-year success rate of ≈80%. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04524364.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014069
003      
CZ-PrNML
005      
20240905134057.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCEP.123.012667 $2 doi
035    __
$a (PubMed)38655693
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a De Potter, Tom $u OLV Hospital, Dienst Cardiologie, Aalst, Belgium (T.D.P.) $1 https://orcid.org/000000031424114X
245    10
$a Predictors of Success for Pulmonary Vein Isolation With Pulsed-field Ablation Using a Variable-loop Catheter With 3D Mapping Integration: Complete 12-month Outcomes From inspIRE / $c T. De Potter, M. Grimaldi, M. Duytschaever, A. Anic, J. Vijgen, P. Neuzil, H. Van Herendael, A. Verma, A. Skanes, D. Scherr, H. Pürerfellner, G. Rackauskas, P. Jais, VY. Reddy, inspIRE Trial Investigators
520    9_
$a BACKGROUND: We previously presented the safety and early efficacy of the inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed-field Ablation [PFA] System With Irreversible Electroporation [IRE]). With the study's conclusion, we report the outcomes of the full pivotal study cohort, with an additional analysis of predictors of success. METHODS: InspIRE was a prospective, multicenter, single-arm clinical trial of drug-refractory paroxysmal atrial fibrillation. Pulmonary vein isolation was performed with a variable-loop circular catheter integrated with a 3-dimensional mapping system. Follow-up with 24-hour Holter was at 3, 6, and 12 months, as well as remote rhythm monitoring: weekly from 3 to 5 months, monthly from 6 to 12 months, and for symptoms. The primary effectiveness end point (PEE) was acute pulmonary vein isolation plus freedom from any atrial arrhythmia at 12 months. Additional subanalyses report predictors of PEE success. RESULTS: The patient cohort included 186 patients: aged 59±10 years, female 30%, and CHA2DS2-VASc 1.3±1.2. The previously reported primary adverse event rate was 0%. One serious procedure-related adverse event, urinary retention, was reported. The PEE was achieved in 75.6% (95% CI, 69.5%-81.8%). The clinical success of freedom from symptomatic recurrence was 81.7% (95% CI, 76.1%-87.2%). Simulating a monitoring method used in standard real-world practice (without protocol-driven remote rhythm monitoring), this translates to a freedom from all and symptomatic recurrence of 85.8% (95% CI, 80.8%-90.9%) or 94.0% (95% CI, 90.6%-97.5%), respectively. Multivariate analyses revealed that left ventricular ejection fraction ≥60% (adjusted odds ratio, 0.30) and patients receiving ≥48 PFA applications (adjusted odds ratio, 0.28) were independent predictors of PEE success. Moreover, PEE success was 79.2% in patients who received ≥12 PFA applications per vein compared with 57.1% in patients receiving fewer PFA applications. CONCLUSIONS: The inspIRE study confirms the safety and effectiveness of pulmonary vein isolation using the novel 3-dimensional mapping integrated circular loop catheter. An optimal number of PFA applications (≥48 total or ≥12 per vein) resulted in an improved 1-year success rate of ≈80%. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04524364.
650    _2
$a lidé $7 D006801
650    12
$a venae pulmonales $x chirurgie $x patofyziologie $7 D011667
650    _2
$a ženské pohlaví $7 D005260
650    12
$a fibrilace síní $x chirurgie $x patofyziologie $x diagnóza $7 D001281
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a katetrizační ablace $x přístrojové vybavení $x metody $x škodlivé účinky $7 D017115
650    _2
$a prospektivní studie $7 D011446
650    _2
$a senioři $7 D000368
650    _2
$a časové faktory $7 D013997
650    _2
$a srdeční frekvence $7 D006339
650    _2
$a akční potenciály $7 D000200
650    _2
$a elektrokardiografie ambulantní $x přístrojové vybavení $7 D015716
650    _2
$a recidiva $7 D012008
650    _2
$a srdeční katétry $7 D062906
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a výsledek terapie $7 D016896
650    _2
$a zobrazování trojrozměrné $7 D021621
650    _2
$a rizikové faktory $7 D012307
650    _2
$a design vybavení $7 D004867
650    _2
$a elektrofyziologické techniky kardiologické $7 D022062
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky $7 D016430
700    1_
$a Grimaldi, Massimo $u Ospedale Generale Regionale "F. Miulli" UOC Cardiologia, Bari, Italy (M.G.) $1 https://orcid.org/0000000293478884
700    1_
$a Duytschaever, Mattias $u AZ Sint Jan, Brugge, Belgium (M.D.) $1 https://orcid.org/0000000184510013 $7 xx0257832
700    1_
$a Anic, Ante $u University Hospital Center Split, Split, Croatia (A.A.) $1 https://orcid.org/0000000268643999
700    1_
$a Vijgen, Johan $u Jessa Hospitals, Hasselt, Belgium (J.V.) $1 https://orcid.org/0000000349284836
700    1_
$a Neuzil, Petr $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic (P.N.) $1 https://orcid.org/0000000343348165
700    1_
$a Van Herendael, Hugo $u Ziekenhuis Oost, Genk, Belgium (H.V.H.)
700    1_
$a Verma, Atul $u McGill University Health Center, Montréal, Canada (A.V.) $1 https://orcid.org/0000000210209727
700    1_
$a Skanes, Allan $u University of Western Ontario, London, Canada (A.S.) $1 https://orcid.org/0000000183328551
700    1_
$a Scherr, Daniel $u Medical University Graz, Graz, Austria (D.S.)
700    1_
$a Pürerfellner, Helmut $u Ordensklinikum Linz GmbH, Linz, Austria (H.P.) $1 https://orcid.org/0000000289658495
700    1_
$a Rackauskas, Gediminas $u Centre for Cardiology & Angiology, Department of Cardiovascular Diseases, Vilnius University, Lithuania (G.R.) $1 https://orcid.org/0000000332724380
700    1_
$a Jais, Pierre $u IHU LIRYC ANR-10-IAHU-04, Centre Hospitalier Universitaire Bordeaux, Bordeaux University, Bordeaux, France (P.J.) $1 https://orcid.org/0000000247007811
700    1_
$a Reddy, Vivek Y $u Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, NY; Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic (V.Y.R.) $1 https://orcid.org/0000000256384993
710    2_
$a inspIRE Trial Investigators
773    0_
$w MED00159578 $t Circulation. Arrhythmia and electrophysiology $x 1941-3084 $g Roč. 17, č. 5 (2024), s. e012667
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38655693 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134051 $b ABA008
999    __
$a ok $b bmc $g 2143695 $s 1225935
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 17 $c 5 $d e012667 $e 20240424 $i 1941-3084 $m Circulation. Arrhythmia and electrophysiology $n Circ Arrhythm Electrophysiol $x MED00159578
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace